Seeking Alpha
18 Jun 2026, 19:41 UTC · 2h ago
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
18 Jun 2026, 19:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has approved Utebzi, the first oral carbapenem for complicated urinary tract infections. — FDA approval of a first-in-class drug is a primary value-inflection point for biotech companies.
+0.80Spero Therapeutics is eligible for milestone payments and royalties from GSK, with potential annual earnings of ~$50m. — Direct revenue streams and milestones provide concrete valuation support and improve cash flow.
+0.60Spero maintains a low burn rate with a funding runway extending into 2028. — Extended cash runway reduces the immediate risk of dilutive financing rounds.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
FDA approval of Utebzi provides a path to milestone payments, royalties, and long-term funding runway.
The company received FDA approval for a new oral carbapenem for urinary tract infections.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
7h ago
